Epstein-Barr virus (EBV)-associated epithelial cancers, including nasopharyngeal carcinoma (NPC) and approximately 10% of gastric cancers, termed EBVaGC, represent 80% of all EBVrelated malignancies. However, the exact role of EBV in epithelial cancers remains elusive. Here, we report that EBV functions in vasculogenic mimicry (VM). Epithelial cancer cells infected with EBV develop tumor vascular networks that correlate with tumor growth, which is different from endothelial-derived angiogenic vessels and is VEGF-independent. Mechanistically, activation of the PI3K/AKT/mTOR/HIF-1α signaling cascade, which is partly mediated by LMP2A, is responsible for EBV-induced VM formation. Both xenografts and clinical samples of NPC and EBVaGC exhibit VM histologically, which are correlated with AKT and HIF-1α activation. Furthermore, although anti-VEGF monotherapy shows limited effects, potent synergistic antitumor activities are achieved by combination therapy with VEGF and HIF-1α-targeted agents. Our findings suggest that EBV creates plasticity in epithelial cells to express endothelial phenotype and provides a novel EBV-targeted antitumor strategy.
Results EBV infection promotes VM formation. To investigate the role of EBV in epithelial cancers, we first established EBV-infected NPC cell lines as previously described 24, 25 . Three typical NPC cell lines, CNE2, TW03, and HNE1, were infected with recombinant EBV derived from the Burkitt's lymphoma cell line Akata-EBV. In situ hybridization confirmed the presence of EBER in the majority of cells in the EBV-infected cultures ( Supplementary  Fig. 1 ). Interestingly, EBV-negative and EBV-positive cell pairs displayed different morphologies: the parental EBV-negative NPC cells exhibited a cobblestone shape typical of epithelial cells, while the EBV-positive cells adopted an elongated spouting shape (Fig. 1a) . Next, we defined the growth patterns of these cells in 3D culture system. Strikingly, when seeded on a Matrigel surface, the EBV-positive cells formed loops and networks, while the EBVnegative cells spread evenly on the matrix surface (Fig. 1b) . To further define the structure of the tubular networks, scanning electron microscopy was performed on the 3D cultures. This approach confirmed that the structures formed by EBV+ NPC cells were indeed tubular and were lined externally with tumor cells (Fig. 1c) . The vessel-like structures resembled a phenomenon called VM, the process in which cancer cells form microvascular channels independent of angiogenesis 15 . To evaluate the VM formation in vivo, EBV− and EBV+ CNE2 cells were injected subcutaneously into nude mice. Twenty days post-implantation, the xenografts were dissected and examined for VM structures by double staining for the endothelial cell marker CD31 and periodic acid-Schiff (PAS), a reagent that detects polysaccharides outlining the basement membrane. The VM structure criteria were as follows: (1) vascular-like channels that were lined with EBER+ tumor cells; (2) positive for PAS but negative for CD31 (PAS + /CD31 − ); and (3) containing erythrocytes inside the channel, as demonstrated with H&E counterstaining (red arrows). Compared with the isogenic parental cells, CNE2 cells infected with EBV dramatically exacerbated tumor growth in the xenograft model (Fig. 1d, e) , and the tumors derived from EBV+ cells exhibited more VM structures (pink arrows) than those derived from EBV− NPC cells (Fig. 1f) , suggesting that EBV infection promotes the VM formation and tumorigenicity of NPC cells. Collectively, both the in vitro and in vivo data suggested that EBV plays an important role in VM.
Elimination of EBV decreases VM formation. Next, we assessed the effects of the clearance of EBV genomes on VM formation. To this end, EBV nuclear antigen 1 (EBNA1), an essential gene for EBV maintenance and replication 26 , was deleted using CRISPR/ Cas9 technology in two NPC cell lines (CNE2 and TW03) infected with Akata-derived EBV, and C666-1, the only NPC cell line containing the original-infecting EBV genome 27 . Two guide RNAs (gRNAs) targeting different regions of EBNA1 ending with a 5′NGG3′ protospacer-adjacent motif (PAM) sequence were used as described in a previous study 28 (Fig. 2a) . The editing efficiency of the gRNAs was confirmed by T7E1 assay (Supplementary Fig. 2a) , and the down-regulation of EBNA1 by the CRISPR/Cas9 system was demonstrated by Western blot analysis (Fig. 2b) . Next, the EBV genome content was analyzed. Upon transduction of EBNA1 gRNAs into CNE2 cells containing EBV-GFP virions, an~60% reduction of GFP fluorescence was observed via flow cytometry ( Fig. 2c and Supplementary Fig. 2b ) and fluorescence microscopy analyses ( Supplementary Fig. 2c ). Furthermore, quantitative PCR with primers for the EBV BALF5 DNA polymerase gene also showed a significant reduction in EBV copy number in NPC-EBV cells following EBNA1-deletion (Fig. 2d) , indicating that the viral genome had been successfully destructed by the CRISPR/Cas9 system. In line with the EBV infection data, clearance of EBV by CRISPR/Cas9 in NPC-EBV cells significantly decreased the percentage of cells displaying the elongated spouting shape (Fig. 2e ) and the number of tubes formed on Matrigel ( Fig. 2f and Supplementary Fig. 2d ). In addition, using a dominant-negative mutant of EBNA1 (dnEBNA1) containing the DNA-binding/dimerization domain to compete against wild-type EBNA1 homodimers from binding to origin of replication (oriP) and thereby interrupting the maintenance of EBV episomes 29 , we showed that abrogation of EBNA1 activity had potent inhibitory effect on VM formation (Fig. 2g ). More importantly, EBNA1 deletion led to a decreased tumor burden and decelerated tumor growth over time (Fig. 2h ) compared with those of the parental cells with intact EBV genome. Collectively, these results indicated that the VM formation of NPC cells depends on the existence of EBV.
Transcriptome analysis reveals hallmarks of VM in NPC-EBV. To gain mechanistic insights into VM formation by EBV infection, we compared global gene expression profiles of the paired EBV-positive and EBV-negative cells (CNE2-EBV vs. CNE2 and TW03-EBV vs. TW03) using RNA-seq analysis. In total, 4644 and 3634 differentially expressed genes (DEGs) (fold change ≥ 2) were found in CNE2 and TW03 cell pairs, respectively (Fig. 3a) . Functional profiling of the 1399 overlapping DEGs suggested that the affected genes were enriched in biological processes including PI3K-AKT pathway, proteoglycans in cancer, TNF signaling pathways and others (Fig. 3b) . Importantly, Gene Ontology (GO) function classification showed that processes including endothelial cell development, endothelial cell migrations and angiogenesis-related genes were differentially expressed in EBVnegative and EBV-positive NPC cell pairs, indicating that EBV
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infection might change the expression of VM-related genes (Fig. 3c) . Therefore, we focused on the DEGs that were associated with neovascularization, including vascular development and tube morphogenesis. A total of 39 genes in these groups were consistently up-regulated in the two EBV-positive cell lines compared with their EBV-negative counterparts and after EBV genome destruction (Fig. 3d, e) . The upregulation of these genes were further confirmed by IHC staining in NPC samples. Using 10 EBV-positive and 7 EBV-negative NPC biopsies (see Methods for detailed sample information), we showed that some DEGs in Fig. 3d, including F3 , CYR61, EphA2, and TNFRSF12A, were indeed upregulated in EBV-positive NPC samples (Fig. 3f) . The above analysis indicated that the 39 vasculogenesis-related genes may account for EBV-induced VM formation.
HIF-1α is required for EBV-induced VM formation. To investigate the regulatory mode of the aforementioned vasculogenesis-related genes upregulated by EBV infection, a search for promoter modules of these genes was conducted. Strikingly, promoters for 36 out of 39 vasculogenesis-related genes were found to harbor the HIF-1-response element (HRE) consensus sequence 5′-RCGTG-3′ 30 ( Supplementary Fig. 3 ). HIF-1 is a heterodimeric transcription factor consisting of an oxygensensitive subunit HIF-1α and a constitutively expressed HIF-1β subunit, which plays a critical role in VM formation 22, 31, 32 EPHA2  TNFRSF12A  FOSL1  KLF4  TGM2  FGF2  FGF2  AREG  VEGFC  SRPX2  ETV5  SPRY2  CSF1  FZD4  ECM1  HYAL1  IL6  SLC12A6  FZD8  NKX3-1  NKX3-1  SOX9  VANGL2  ECSCR  UTS2  NRP1  CEACAM1  XDH  ZEB1  RAPGEF3  ROBO4  ACVRL1  ACVRL1  PTPRB  NTRK1  LBX1  CX3CL1  DLC1  FGF1  FGF1 Fig. 4f and Supplementary Fig. 4d ), while the cell viability was not affected below the concentration of 10 μM (Supplementary Fig. 4e ). Similar observations were obtained by using 2MeOE2, another HIF-1α inhibitor that blocks HIF-1α accumulation and activity 34 ( Fig. 4g, h ). Furthermore, knockdown of HIF-1α with specific siRNAs severally impaired VM formation of EBV-infected cells (Fig. 4i , j). These data indicate that EBVinduced HIF-1α activation contributes to VM formation.
EBV increases HIF-1α synthesis via PI3K-AKT-mTOR pathway. In addition to hypoxia, pathways involved in oncogenic activation also activate HIF-1α in an oxygen-independent manner, such as loss of PTEN and VHL and gain-of-function mutations in oncogenes in PI3K-AKT-mTOR and MAPK pathways 35, 36 . Among these molecules, PI3K-AKT pathway is the most significantly affected pathway in EBV-infected NPC cells (Fig. 3b ). As expected, EBV infection led to an increase in AKT phosphorylation; conversely, elimination of EBV through the CRISPR/Cas9 system reduced AKT phosphorylation to levels similar to that of the EBV-negative control cells (Fig. 5a , b and Supplementary Fig. 5a ). The effect of EBV targeting was specific to EBV-positive cells, as transduction of EBNA-1 gRNAs into EBV-negative NPC cells had no effects on the levels of phospho-AKT and HIF-1α ( Supplementary Fig. 5b ). Additionally, transfection of dominant-negative mutant of EBNA-1 into EBV-positive cells resulted in a marked suppression of AKT phosphorylation and HIF-1α expression (Fig. 5c ). We then treated EBV+ cells with LY294002 and Wortmannin, two inhibitors of PI3K. Both drugs effectively reduced total ( Fig. 5d ) and nuclear HIF-1α accumulation to levels similar to those of the EBV-negative counterparts under normoxic conditions ( and Wortmannin suppressed the in vitro VM formation of EBVinfected NPC cells ( Fig. 5g and Supplementary Fig. 5c , bottom panel) in a dose-dependent manner ( Fig. 5h and Supplementary  Fig. 5d ), indicating the involvement of PI3K-AKT signaling in EBV-induced HIF-1α accumulation and VM formation. AKT affects multiple downstream targets. One of the downstream protein kinases, mTOR (mammalian target of rapamycin), has been implicated in PI3K/AKT-dependent oncogenesis through its regulation of cap-dependent translation initiation by phosphorylating two downstream effectors, eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1) and p70 S6 kinase (S6K) 37, 38 . Notably, it has been shown that the mTOR pathway increases HIF-1α translation driven by the 5' UTR region of HIF-1α 39 . We then treated CNE2-EBV cells with the mTOR inhibitor rapamycin and the S6K inhibitor PF-4708671 to delineate the mTOR pathway in EBV-induced HIF-1α. The accumulation of HIF-1α in EBV-infected cells was highly sensitive to mTOR and S6K inhibitors to a similar extent as with the PI3K inhibitor Wortmannin, while the expression of the EBV immediate-early gene Zta was not affected by these drugs (Fig. 5i) . The capacity of PF-4708671 to inhibit mTOR phosphorylation might be due to the direct phosphorylation of mTOR by S6K 40 . Correspondingly, rapamycin significantly inhibited VM network formation of CNE2-EBV cells (Fig. 5j) . We also compared the degradation rate of HIF-1α in EBV-negative and EBV-positive CNE2 cells and the results suggested that the presence of EBV did not decelerate HIF-1α degradation; besides, HIF-1α hydroxylation, which is required for the interaction with VHL E3 ubiquitin ligase, was not inhibited by EBV infection, suggesting that EBV does not contribute to HIF-1α stabilization ( Supplementary Fig. 5e ). Together, these results indicate that EBV promotes VM formation through PI3K/AKT/mTOR-mediated HIF-1α synthesis.
LMP2A regulates VM formation through the AKT/HIF-1α axis. Having established the role of EBV in promoting VM, we next tried to identify the viral genes that contribute to VM formation. As EBV typically exists in latency, we first examined the latent gene expression patterns in EBV-infected NPC cell lines. RT-PCR results suggested that EBNA1, LMP1, and LMP2A were all expressed in CNE2-EBV, HNE1-EBV, and C666-1 cells, while LMP2B transcript was absent in C666-1 cells as described previously 27 ; on the contrary, the transcription of latency III antigen EBNA2 was only detected in the B-cell line, B95-8 ( Fig. 6a) , therefore the expression pattern of EBV-infected NPC cells corresponded to type II latency, the same as in NPC tumors. Among these latent genes, LMP1 and LMP2A have been implicated in AKT activation. However, given that LMP1 is detected in only 10-20% of NPCs by immunohistostaining 8 and could not be detected by Western blots of C666-1 cells 27 , and as LMP1 is often absent in EBVaGC 4,5 , we focused on LMP2A, an EBV oncoprotein constitutively activates AKT 41, 42 and mTOR pathways 43 and is more consistent in NPC 7 . As expected, overexpression of LMP2A in NPC cells (CNE2 and HNE1) led to increases in the Fig. 3 ) with the exception of three genes colored in green. e The average FPKM values of the DEGs in d. ns: not significant (one-tailed Wilcoxon matched pairs test). f (left) Serial sections of EBV-negative and EBV-positive NPC tissues were stained with H&E, EBER and antibodies targeting F3, CYR61, EphA2 and TNFRSF12A. Scale bars = 500 μm. (right) IHC scores of the indicated genes in 10 EBV-positive and 7 EBV-negative NPC biopsies. Means ± SD, **p < 0.01, two-tailed Mann-Whitney test levels of phosphorylated AKT, mTOR, 4E-BP1, S6K and ribosomal protein S6, accompanied by upregulation of HIF-1α (Fig. 6b) . Furthermore, NPC cells overexpressing LMP2A readily formed tubes on Matrigel, which was not evident in cells transfected with empty vector (Fig. 6c) . More importantly, knockdown of LMP2A with siRNA reduced HIF-1α expression and PI3K/AKT/mTOR signaling axis activation (Fig. 6d) , as well as the tube-forming capacities of EBV-infected NPC cells (Fig. 6e) , supporting an important role for LMP2A in EBV-induced VM formation.
EBV links to VM formation in EBV-associated carcinomas. Next, we investigated the correlation between AKT/HIF-1α activity and VM formation in xenografts and human NPC and gastric carcinoma tissues. Xenografts derived from EBV-infected CNE2 cells showed increased AKT phosphorylation, HIF-1α nuclear accumulation and VM structure compared with EBVnegative CNE2-derived tumors (Supplementary Fig. 6a ). We further investigated VM formation in human NPC tissues. The VM channels positive for PAS and negative for CD31 (pink arrows) were lined with EBER-positive tumor cells and contained red blood cells (Fig. 7a, top panel) . Quantification of IHC staining results demonstrated that the PAS + CD31 − NPC tumor cells expressed high levels of EBER, phospho-AKT, and HIF-1α (Fig. 7b) . These data confirmed the existence of VM in NPC clinical samples and further demonstrated the association between EBV infection, VM formation, and AKT/HIF-1α activation.
To determine whether the effect of EBV on VM formation was limited to NPC or also applied to other EBV-associated tumors, we examined VM formation in EBV− and EBV+ gastric carcinomas, the latter of which is known as EBV-associated gastric carcinoma (EBVaGC). An in vitro VM assay using a pair of EBV− and EBV+ gastric carcinoma cell lines, AGS and AGS-EBV, along with two EBV-positive gastric carcinoma cell lines, GT38 and GT39, demonstrated that EBV-positive gastric carcinoma cells formed tubes on 3D Matrigel culture, which did not occur in the EBV-negative AGS cells ( Supplementary  Fig. 6b, c) . More importantly, histological analysis of human gastric carcinoma tissues suggested that EBVaGC displayed more VM structures and expressed higher levels of phospho-AKT and nuclear HIF-1α than did EBV-negative gastric carcinoma tissue (Fig. 7a, bottom panel and c) , indicating that EBV plays a general role in VM formation via the AKT/HIF-1α axis in EBVassociated epithelial malignancies.
Synergistic effect of anti-VM and anti-VEGF therapy in NPC.
VEGF is a key tumor angiogenesis factor and is regulated by HIF-1α. As EBV infection led to HIF-1α accumulation, we next c CNE2-EBV cells were transfected with empty vector or a dominant-negative mutant of EBNA1 (dnEBNA1), followed by WB analysis using antibodies as indicated. d Immunoblots of AKT phosphorylation and HIF-1α expression following LY294002 (50 μM) or Wortmannin (1 μM) treatment for 6 h. e Immunoblots of HIF-1α distribution in cytoplasmic and nuclear fractions of EBV-and EBV+ NPC cells following LY294002 (50 μM), Wortmannin (1 μM) or DMSO treatment for 6 h. f Immunofluorescence of phospho-AKT (S473) and HIF-1α in TW03-EBV cells after 6 h of treatment with DMSO, LY294002 (50 μM) or Wortmannin (1 μM). Scale bars = 50 μm. g Microscopy of tube formation on Matrigel in TW03-EBV cells after 12 h of treatment with LY294002 (50 μM) or Wortmannin (1 μM). Scale bars = 100 μm. h Quantification of tube numbers formed by NPC-EBV cells following LY294002 or Wortmannin treatment. Mean ± SD, n = 5, two-tailed unpaired t-test. i Effects of PI3K/mTOR/S6K kinase inhibitors on EBV-induced HIF-1α expression. CNE2-EBV cells were treated with DMSO, 1 μM Wortmannin (Wort), 0.5 μM rapamycin (Rapa) or 10 μM PF-4708671 (PF) for 6 h under normoxic conditions prior to immunoblotting with antibodies, as indicated. j Effect of rapamycin (0.5 μM) on VM channel formation of CNE2-EBV cells. Mean ± SD, n = 5, two-tailed unpaired t-test. ns: not significant, *p < 0.05, ***p < 0.001 investigated the involvement of VEGF in EBV-induced VM formation. Indeed, EBV infection increased VEGF secretion (Supplementary Fig. 7a ). However, blocking autocrine VEGF by antihuman VEGF neutralization antibody (NAb) did not have an appreciable effect on the tube formation of EBV-infected NPC cells; in contrast, a strong inhibition of the tube formation of human umbilical vein endothelial cells (HUVECs) was observed following VEGF NAb treatment (Supplementary Fig. 7b ). Additionally, treatment of EBV-positive NPC cells with Axitinib, a selective inhibitor of VEGF receptors, did not affect in vitro VM formation ( Supplementary Fig. 7c ), indicating that VEGF did not contribute to the EBV-induced VM.
Based on the above findings, we proposed that concurrent targeting of VEGF-mediated classic angiogenesis and VM might achieve maximal antitumor efficacy in EBV-associated tumors. Therefore, we evaluated the effects of anti-VEGF or anti-HIF-1α monotherapy and combination therapy in NPC xenografts. Treatment with the HIF-1α inhibitor PX-478 or the VEGFR inhibitor Axitinib alone only showed modest anti-tumor effects. In contrast, combination of PX-478 and Axitinib induced a significantly more pronounced tumor inhibition (Fig. 8a, b) . We then assessed tumor neovascularization by histological double staining of CD31 and PAS. Tumors from the control group were enriched in both ECs and VM channel-like structures, and treatment with Axitinib decreased CD31 + microvessels (brown) without affecting VM formation (PAS + /CD31 − , pink), whereas PX-478 treatment led to large areas of VM loss without a significant reduction in microvessels. Notably, the combination of Axitinib and PX-478 caused marked decreases in both microvessels and VM (Fig. 8c-e) . These results suggest that targeting VEGF and HIF-1α has synergistic anti-angiogenic effects, providing a novel therapeutic option for EBV-associated tumors.
Discussion
EBV was the first human DNA tumor virus discovered over 50 years ago 1 . EBV has been linked to the development of cancers originating from both lymphoid and epithelial cells. However, the contribution of the virus to epithelial cell tumors is less clear. but is generally believed to be a consequence of the aberrant establishment of virus latency in epithelial cells that undergo premalignant genetic changes 3, 7 . Although EBV infection may not be the initiating event for epithelial cell tumors, EBV has been shown to change the host gene expression profile and signaling networks to endow cancerous properties, including increased cell survival, proliferation, invasion, angiogenesis, immune evasion, EMT, and acquisition of stemness features 3, 8, 9, 44, 45 . In this study, we show that EBV infection confers neovascular features in epithelial cancers by promoting VM formation. Cells infected with , twice a day), PX-478 (5 mg kg −1 p.o., every 2 days) alone or Axitinib plus PX-478. b Growth curves of CNE2-EBV xenograft tumors after treatment with vehicle, Axitinib or/and PX-478. Mean ± SD, n = 10, ***p < 0.001 versus the other three treatment groups (two-tailed Mann-Whitney test). c H&E, PAS and mouse CD31 staining of CNE2-EBV xenograft sections. Red lines: necrotic area. White scale bars = 100 μm, black scale bars = 50 μm. d Numbers of endothelial cell (EC) channel-like structures in CNE2-EBV xenograft tumors from mice treated with vehicle, Axitinib or/and PX-478. Channels were determined under a microscope with 400× magnification in randomly chosen fields. Mean ± SD, n = 5, two-tailed Mann-Whitney test. e Number of VM channel-like structures in CNE2-EBV xenografts counted as in d. f Working model illustrating the mechanism by which EBV promotes VM and the aggressiveness of carcinomas such as NPC and EBVaGC. ns: not significant, *p < 0.05, ***p < 0.001 EBV readily form an extensive network of tube-like structures in vitro that is reminiscent of endothelial blood vessels; furthermore, VM structures, as defined by PAS + /CD31 − staining, were evident in NPC and EBVaGC biopsies. Our finding that epithelial cells infected with EBV phenotypically mimic endothelial-like cells further indicates that EBV creates plasticity in host cells. It is widely accepted that tumors require blood supply for growth; these vasculogenic-like networks induced by the virus could serve as an intratumoral fluid-conducting meshwork to contribute to the growth advantage of EBV-infected tumors.
EBV infection leads to the epigenetic changes, involving DNA methylation and histone modifications, and signaling pathway aberrations in host cells 8, 46 . Our transcriptome analysis revealed that vasculogenesis-related genes were upregulated in EBVinfected epithelial cells. Interestingly, the promoters of most of these genes contain the HRE motif (Supplementary Fig. 3 ). HIF-1α is constitutively stabilized in normoxic EBV-associated tumors, and inhibition of HIF-1α by PX-473 suppressed the VM phenotype and xenograft tumor progression, highlighting the importance of HIF-1α in VM formation and the optimal growth of EBV-associated tumors. The relationship between EBV latent genes and HIF-1α is complex. For example, LMP1 has been shown to enhance HIF-1α synthesis through ERK1/2 MAPK signaling 47 ; LMP1 has also been demonstrated to stabilize HIF-1α through down-regulation of prolyl hydroxylases 48 . In addition, EBNA1 promotes HIF-1α transcription in NPC cells 49 , and EBNA3A stabilizes HIF-1α via binding to prolyl hydroxylases in B lymphocytes 50 . However, these above-mentioned studies were mostly performed by overexpressing of a single EBV gene, which could not fully recapitulate the biological phenotype of natural EBV infection. In this study, we established isogenic EBVnegative and EBV-positive NPC cells and demonstrated that the PI3K/AKT pathway, the most significantly perturbed pathway following EBV infection, mediates primarily non-hypoxic HIF-1α regulation in EBV-infected epithelial cells. Mechanistically, EBV drives HIF-1α synthesis through PI3K-AKT-mTOR-mediated protein translation, but plays little roles in HIF-1α transcription and protein degradation (Supplementary Fig 4a, 5e ). mTOR is a key downstream mediator in the PI3K/AKT signaling pathway that plays a central role in regulating cap-dependent translation of HIF-1α 39 . Among latent proteins, both LMP1 and LMP2A contribute to AKT 8, 41, 42 and mTOR activation 43, 51 . However, LMP1 expression is variable in NPC and is often absent in EBVaGC 4, 5 , and it has been shown that LMP1 is not associated with HIF-1α expression in NPC tissues 52 . On the contrary, LMP2A expression is consistently detected in various EBVassociated malignancies, pointing out its essential role in pathogenesis. LMP2A is an integral membrane protein whose amino terminus recruits tyrosine kinases Lyn and Syk to activate PI3K-AKT signaling 8 . We demonstrated that LMP2A is required for PI3K/AKT/mTOR/HIF-1α cascade activation and the VM formation driven by EBV (Fig. 8f) . Whether LMP2A coordinates with other EBV genes/miRNAs to orchestrate HIF-1α expression and VM formation needs further investigation.
On the other side, VM might be attributable to the maintenance of viral latency as the tumor enlarges. Latent infection is known to be necessary for virus persistence and immune evasion. Solid tumors develop regions of hypoxia when they outgrow their blood supply, and it has been demonstrated that hypoxia reactivates EBV to lytic replication through binding to the HRE motif on the promoter of the immediate-early BZLF1/Zta gene 53, 54 . As reported, ectopically expression of wild-type and consitutively active (CA) mutant of HIF-1α 55 upregulated Zta mRNA level and protein abundance, and hypoxia-stabilized HIF-1α protein to drive Zta transcription ( Supplementary Fig. 8a-c) . Our study revealed that VM induced by EBV infection is associated with HIF-1α activation. However, abrogation of HIF-1α accumulation by pharmacological targeting PI3K/AKT/mTOR pathway, or by depletion of LMP2A in EBV-infected cells, did not lead to reduction in Zta level (Figs. 5h and 6d) , indicating that the extent of non-hypoxic HIF-1α upregulation driven by EBV does not reach the threshold for virus lytic activation as hypoxia does. Establishment of a greater oxygen delivery capacity while maintaining long-term persistent viral infection may be the physiological significance of VM formation and is a survival strategy of EBV, which could be a required step in the progression of EBVassociated carcinomas.
Our results suggest that VM status should be taken into account for anti-angiogenic therapy in patients with EBVassociated epithelial cancers. Angiogenesis has been considered as a promising treatment target in NPC. Bevacizumab, a chimeric monoclonal antibody targeting VEGF, has been evaluated in a Phase II multinational trial in combination with standard chemoradiation treatment in 46 NPC patients 13 . Another tyrosine kinase inhibitor targeting VEGF receptor, sunitinib, has been tested in a Phase II study in 13 metastatic NPC patients 12 .
However, these studies have been discontinued because of severe hemorrhagic events, even though patients showed tumor shrinkage. Furthermore, VEGF inhibition may cause a hypoxic and acidic microenvironment, which accelerates tumor progression 56 . Therefore, targeting alternative neovascularization pathways might be a logical way to overcome the resistance to anti-VEGF therapy. Our approach to use combination therapy with Axitinib and PX-478 provides a means to circumvent the development of resistance to conventional antiangiogenesis therapy, and the finding of the role of HIF-1α in EBV-induced VM opens a new avenue to further explore the clinical use of HIF-1α inhibitors in NPC and EBVaGC. In addition to HIF-1, targeting additional stages in VM signaling, such as inhibition of mTOR pathway using rapamycin analogs, would achieve similar therapeutic effects. Further studies of the molecular pathways that regulate EBV-induced VM formation could lead to new strategies to target EBV-associated epithelial cancers and could provide new perspectives on EBV-induced tumor cell plasticity.
Methods
Cell culture. Akata-EBV-GFP is an Akata Burkitt lymphoma cell line carrying the Akata bacterial artificial chromosome (BAC) with a GFP tag, B95-8 is an EBVproducing marmoset B-cell line, both were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS) (Hyclone). The NPC cell lines CNE2, HNE1, TW03, and C666-1 were cultured in RPMI-1640 with 5% FBS. B cell lines and NPC cell lines were from Prof. Mu-Sheng Zeng (Sun Yat-sen University Cancer Center). The gastric carcinoma cell lines AGS, AGS-EBV, GT38, and GT39 were kindly provided by Prof. Rui-Hua Xu (Sun Yat-sen University Cancer Center) and cultured in DMEM (Hyclone) with 5% FBS. All cell lines were routinely tested and shown to be Mycoplasma-free as determined by PCR-based method (16S rDNA-F: 5′-ACTCC TACGGGAGGCAGCAGTA-3′, 16S rDNA-R: 5′-TGCACCATCTGTCACTCTG TTAACCTC-3′).
Establishment of EBV-infected cells. For EBV production, Akata-EBV-GFP cells were treated with 0.8% (v/v) goat anti-human IgG for 6 h to induce EBV transition from the latent phase into the lytic cycle. After culture in fresh medium for 3 days, the supernatants were collected by centrifugation at 20,000×g for 30 min at 4 ℃. The pellets were resuspended in 10% FBS DMEM and used for cell-free infection. The infected CNE2, HNE1, TW03, and AGS cells were sorted using flow cytometry (Beckman) and were maintained in culture medium containing 300-700 μg mL −1 G418 (Invitrogen). The infection was verified by in situ hybridization (ISH) of EBER according to the manufacturer's instructions for the EBER ISH kit (Zhongshan Jinqiao Bio. Co.).
Western blot analysis. Cells were lysed in SDS-loading buffer, the lysates were resolved on SDS-PAGE and transferred to PVDF membrane (Millipore). The blots were then incubated with species-specific HRP-conjugated secondary antibodies, and the immunoreactive bands were visualized by enhanced chemiluminescence (ECL, Pierce). Full Western blot images are shown in Supplementary Fig. 9 .
Animal studies. All of the animal experiments were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (reference no. L102042016110W), and the animals were handled in accordance with institutional guidelines. Female BALB/c nude mice (4-6 weeks old) purchased from Shanghai Laboratory Animal Center were inoculated subcutaneously in the right flanks with 5 × 10 6 CNE2 and CNE2-EBV cells. Tumor volume (V) was measured by caliper every 2 days for the duration of the experiment and calculated with the formula V = (length × width 2 )/2.
For antitumor drug assessment, when tumors reached 100-200 mm 3 , the mice were randomized divided into four groups (n = 10 for each group). The control group received vehicle (0.5% sodium carboxymethyl cellulose (CMC)) daily, and the treatment groups received either Axitinib (30 mg kg −1 p.o., twice daily) alone, PX-478 (5 mg kg −1 p.o., every two days) alone or a combination of Axitinib and PX-478. Tumor sizes were measured every other day. At the end of the experiment, mice were euthanized, and tumors were harvested and weighed.
In vitro tube formation assay. Briefly, 30 μL of Matrigel (BD) was plated in 96-well plates and incubated at 37°C for 30 min to allow polymerization. Next, 1 × 10 5 cells per well were added to the Matrigel layer and grown for 12 h. Randomized fields were captured using an inverted microscope, and tubes were quantified from each image. Data are presented as the average number of tubes ± SD.
Scanning electron microscopy. For scanning electron microscopy, EBV-positive NPC cells were added to the Matrigel-treated coverslips for 12 h and then fixed in 2.5% cold glutaraldehyde in 0.1 M of sodium cacodylate buffer (pH 7.4). Specimens were dehydrated in a graded series of ethanol, transferred in acetone and isoamyl acetate and then subjected to critical point drying with CO 2 in a HITACHI HCP-2. Dried samples were sputter-coated with gold with a Giko IB.5 ion coater before scanning electron microscopy (FEI QUANTA 200, 20 kV) observation.
Clinical specimens. Clinical sample collection from human patients was approved by the Human Research Ethics Committee of the Sun Yat-sen University cancer center (GZR2016-105), and written informed consent was obtained from all participants. In total, 10 cases EBV-positive (seven males and three females from ages 42 to 61, all are primary NPC tumors) and seven cases EBV-negative NPCs (five males and two females from ages 35 to 70, including one case of primary tumor and six cases of recurrent tumors), five cases of EBV-positive (five males from ages 33 to 53) and seven cases of EBV-negative human gastric carcinoma (four males and three females from ages 48 to 84) were obtained from Sun Yat-sen University cancer center, Guangzhou, China, from 2010 to 2017, and all of the samples were diagnosed by two pathologists (Dr. Jinping Yuan and Dr. Jianyong Shao, Sun Yatsen University Cancer Center). Ten cases of EBV-positive NPC tumors, one case of primary EBV-negative NPC tumor and human gastric carcinomas had not received anti-tumor treatment before biopsy collection; six cases of recurrent EBV-negative NPCs received intensity modulated radiation therapy(IMRT) with or without platinum-based concurrent chemotherapy.
IHC and PAS staining. IHC was performed on formalin-fixed paraffin-embedded (FFPE) sections of clinical NPC and gastric cancer tissues or xenograft mice tissues. Briefly, the tissues were deparaffinized and rehydrated, and the samples were subjected to citrate-mediated high-temperature antigen retrieval and the samples were incubated with the primary antibodies at 4°C overnight 57 . A semiquantitative scoring was evaluated as follows: 0 for staining in ≤ 1% of cancer cells, 1 for staining in 2-25% of cancer cells, 2 for staining in 26-50% of cancer cells, 3 for staining in 51-75% of cancer cells, and 4 for staining in ≥ 75% of cancer cells. Staining intensity was scored as 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Staining was repeated at least twice in sequential sections from the same tissue blocks, and the sections were reviewed by two pathologists. The staining index (values 0-12) was obtained by multiplying the intensity by the proportion of immunopositive cells of interest. To detect VM structures, a PAS staining kit (BASO BA-4080A) was applied before hematoxylin counterstaining. the numbers of positive cells were counted from ≥ 5 randomly chosen fields.
Whole-transcriptome sequencing. Total RNA was isolated with TRIzol and purified using the RNeasy Plus Micro Kit (Qiagen) according to the manufacturer's protocol. The RNA libraries were then sequenced using the Illumina HiSeq4000 at the Novogene Genomic Sequencing Center, Beijing, China. The RNA-seq sequence reads were aligned to the reference genome using STAR (v2.5.1b). Differential expression analysis was performed using the DESeq2 R package (1.10.1). The resulting P-values were adjusted using the Benjamini and Hochberg's approach for controlling the false discovery rate. Genes with an adjusted p-value (p adj ) < 0.05 and an absolute fold change of 2 were set as the threshold for significantly differential expression. The alignment results were converted to RNA-seq gene expression measurements as FPKM (fragments per kilobase of exon per million fragments mapped) using HTSeq v0.6.0.
Immunofluorescence and nuclear/cytosol fractionation. Cells were seeded on coverslips and fixed with 4% paraformaldehyde. After washing with PBS, coverslips were incubated with 0.2% Triton X-100 for 5 min. Cells were incubated with the primary antibodies for 1 h and then with Alexa Fluor 594 goat anti-mouse or goat anti-rabbit IgG (Invitrogen) for 1 h. Cells were then counterstained with DAPI (Sigma) and imaged with a confocal laser-scanning microscope (Olympus FV1000) 57 . To quantify the Immunofluorescence intensity, the integrated optical density (IOD) was calculated using Image J software, and the mean IOD (MOD) was calculated from IOD/Area. Nuclear/cytosol fractionation was performed using the Nuclear-Cytosol Extraction Kit (KeyGen, Nanjing, China) according to the manufacturer's instructions.
Statistical analysis. Unless otherwise stated, data with a Gaussian distribution were compared with a two-tailed unpaired t-test or a two-tailed unpaired t-test with Welch's correction if variances were significantly different, as determined by the F-test. Matched samples with a Gaussian distribution were compared with a two-tailed paired t-test. Matched samples with non-Gaussian distribution were compared with a Wilcoxon matched pairs test. Data with a non-Gaussian distribution were compared with a two-tailed Mann-Whitney test. Pearson's correlation coefficient was used to determine the correlations of VM with EBER, AKT phosphorylation and nuclear HIF-1α expression.
